Inhibikase Therapeutics, Inc.
IKT • NASDAQ • Stock Fundamentals
Inhibikase Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Mark T. Iwicki, with a market cap of $224.5M.
Market Cap$224.5M
Employees9.0
CEOMark T. Iwicki
CountryUnited States of America
Healthcare
Biotechnology
Most Recent EarningsMay 12, 2026 · 16 days agoQ1 2026
View reportNext EarningsAug 13, 2026 · in 2 monthsQ2 2026
Financials
Based on Q1 2026 filing
Inhibikase Therapeutics, Inc. FAQ
Common questions about Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $224.5M and trades on NASDAQ.
Inhibikase Therapeutics, Inc. has approximately 9 employees.